Silexion Therapeutics Files 8-K with Financials & Warrants

Ticker: SLXNW · Form: 8-K · Filed: Mar 5, 2025 · CIK: 2022416

Sentiment: neutral

Topics: financial-statements, warrants, corporate-action

Related Tickers: SLXN

TL;DR

Silexion Therapeutics filed an 8-K on 3/5/25 with financials and details on $1.15 warrants.

AI Summary

Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on March 5, 2025, reporting on financial statements and exhibits. The company, incorporated in the Cayman Islands, is based in Ramat Gan, Israel, and operates in the biological products sector. This filing also notes the existence of warrants exercisable for ordinary shares at $1.150 per share.

Why It Matters

This 8-K filing provides updated financial information and details on outstanding warrants, which are crucial for investors to assess the company's financial health and potential dilution.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial statements and exhibits, not indicating any immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report financial statements and exhibits as of March 5, 2025.

What was Silexion Therapeutics Corp.'s former name?

Silexion Therapeutics Corp.'s former name was Biomotion Sciences, with a name change date of May 6, 2024.

Where are Silexion Therapeutics Corp.'s principal executive offices located?

Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.

What is the exercise price for the company's warrants?

The warrants are exercisable for ordinary shares at an exercise price of $1.150 per share.

In which jurisdiction was Silexion Therapeutics Corp. incorporated?

Silexion Therapeutics Corp. was incorporated in the Cayman Islands.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Silexion Therapeutics Corp (SLXNW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing